Barry J. Plant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barry J. Plant has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
Claire Fleming
Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Cork, Ireland
5 shared publicationsDesmond M. Murphy
Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Cork, Ireland
5 shared publicationsTamara Vagg
Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Wilton, Cork, Ireland
5 shared publications- Tamara Vagg
11Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Cork, Ireland
5 shared publications - Damian G. Downey
Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland
4 shared publications Hisham Ibrahim
4 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Bentham Science Publishers Ltd. in The Open Respiratory Medicine Journal
- Vol. 20 (1)
Real-world Clinical Outcomes in Asthma Patients Commenced on or Switched to Dupilumab
Introduction: Ireland has one of the highest asthma rates globally, with an estimated 450,000 individuals diagnosed. For patients with severe asthma who remain uncontrolled despite optimal therapy, biologics targeting Type 2 inflammation, such as dupilumab, offer a promising treatment option. Dupilumab became available for reimbursement in Ireland in November 2023. We aimed to assess the real-world effectiveness of dupilumab in adults with severe asthma, including those previously treated with other biologics. Methods: This retrospective, single-centre study reviewed patients initiated on or switched to dupilumab between November 2023 and November 2024 at Cork University Hospital. Outcomes assessed at baseline and six months included Asthma Control Questionnaire (ACQ) scores, exacerbation frequency, and FEV1. Paired t-tests were used for statistical analysis. Results: Among 39 patients (median age 55 years), 64.1% had prior biologic exposure. Dupilumab significantly improved ACQ scores (mean reduction -0.95, p =0.0003) and reduced exacerbations (mean reduction -2.89, p =0.0004). Improvements were consistent in biologic-naïve and biologic-experienced groups. FEV1 showed a non-significant upward trend ( p =0.1553). Five patients (12.8%) discontinued therapy due to side effects or lack of efficacy. Discussion: These findings support the real-world effectiveness of dupilumab in improving symptom control and reducing exacerbation frequency in patients with severe asthma, including those who have previously received other biologics. Dupilumab became reimbursable in Ireland in late 2023, and data from Irish populations have been limited until now. Conclusion: Dupilumab significantly improved asthma control and reduced exacerbation rates in this real-world cohort, supporting its use in patients with severe asthma, including those switching from other biologic agents.
- 5 November 2026
- Published by Bentham Science Publishers Ltd. in The Open Respiratory Medicine Journal
- Vol. 20 (1)
Open AccessReal-world Clinical Outcomes in Asthma Patients Commenced on or Switched to Dupilumab
Introduction: Ireland has one of the highest asthma rates globally, with an estimated 450,000 individuals diagnosed. For patients with severe asthma who remain uncontrolled despite optimal therapy, biologics targeting Type 2 inflammation, such as dupilumab, offer a promising treatment option. Dupilumab became available for reimbursement in Ireland in November 2023. We aimed to assess the real-world effectiveness of dupilumab in adults with severe asthma, including those previously treated with other biologics. Methods: This retrospective, single-centre study reviewed patients initiated on or switched to dupilumab between November 2023 and November 2024 at Cork University Hospital. Outcomes assessed at baseline and six months included Asthma Control Questionnaire (ACQ) scores, exacerbation frequency, and FEV1. Paired t-tests were used for statistical analysis. Results: Among 39 patients (median age 55 years), 64.1% had prior biologic exposure. Dupilumab significantly improved ACQ scores (mean reduction -0.95, p =0.0003) and reduced exacerbations (mean reduction -2.89, p =0.0004). Improvements were consistent in biologic-naïve and biologic-experienced groups. FEV1 showed a non-significant upward trend ( p =0.1553). Five patients (12.8%) discontinued therapy due to side effects or lack of efficacy. Discussion: These findings support the real-world effectiveness of dupilumab in improving symptom control and reducing exacerbation frequency in patients with severe asthma, including those who have previously received other biologics. Dupilumab became reimbursable in Ireland in late 2023, and data from Irish populations have been limited until now. Conclusion: Dupilumab significantly improved asthma control and reduced exacerbation rates in this real-world cohort, supporting its use in patients with severe asthma, including those switching from other biologic agents.
- Open Access
- 1 October 2026
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 22 (4) , 260059
Digital health in cystic fibrosis across the eHealth life-cycle: why successful innovation requires more than randomised trials
Digital health is increasingly embedded in cystic fibrosis (CF) care, spanning telehealth, mobile applications, remote monitoring, sensors, and data-driven decision support. Despite this rapid growth, CF digital health research remains fragmented, characterised by inconsistent terminology, disciplinary silos, and challenges in translating innovations into routine clinical practice. Many digital health technologies (DHTs) remain confined to small-scale pilots, while technological capability continues to outpace evaluation methodologies. This review applies the “eHealth evaluation cycle” as a structured framework to examine CF digital health research across the full development-to-implementation pathway. By mapping representative CF studies to the stages of conceptualisation, design and usability, feasibility, effectiveness, and implementation, the review highlights both strengths and gaps in the current evidence base. CF digital health research demonstrates notable maturity at the effectiveness stage, with several high-quality trials, but remains comparatively underdeveloped in early conceptual planning and late-stage implementation research. Adopting a life-cycle lens clarifies how evaluation methods should align with intervention maturity and supports more efficient and safer progression of DHTs. Moving forward, CF digital health research must prioritise structured early-phase development, rigorous feasibility work, and dedicated implementation studies to enable sustainable integration into clinical care.
- 1 October 2026
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 22 (4) , 260059
Open AccessDigital health in cystic fibrosis across the eHealth life-cycle: why successful innovation requires more than randomised trials
Digital health is increasingly embedded in cystic fibrosis (CF) care, spanning telehealth, mobile applications, remote monitoring, sensors, and data-driven decision support. Despite this rapid growth, CF digital health research remains fragmented, characterised by inconsistent terminology, disciplinary silos, and challenges in translating innovations into routine clinical practice. Many digital health technologies (DHTs) remain confined to small-scale pilots, while technological capability continues to outpace evaluation methodologies. This review applies the “eHealth evaluation cycle” as a structured framework to examine CF digital health research across the full development-to-implementation pathway. By mapping representative CF studies to the stages of conceptualisation, design and usability, feasibility, effectiveness, and implementation, the review highlights both strengths and gaps in the current evidence base. CF digital health research demonstrates notable maturity at the effectiveness stage, with several high-quality trials, but remains comparatively underdeveloped in early conceptual planning and late-stage implementation research. Adopting a life-cycle lens clarifies how evaluation methods should align with intervention maturity and supports more efficient and safer progression of DHTs. Moving forward, CF digital health research must prioritise structured early-phase development, rigorous feasibility work, and dedicated implementation studies to enable sustainable integration into clinical care.
- Open Access
- 22 May 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e86194
Reporting of Telehealth Implementation in Cystic Fibrosis: Scoping Review Using a Novel Theory-Based Evaluation Lens
Background: Many inductive reviews exploring telehealth and its application in health care have identified missing or inconsistently reported implementation data, calling for a standardized approach to telehealth research. Objective: Using cystic fibrosis (CF) as a case exemplar, this study evaluated the adherence of telehealth research to standardized reporting frameworks through a theory-based evaluation lens to assess implementation reporting quality and identify knowledge gaps and strengths across the literature. Methods: We conducted an updated systematic review of the PubMed, Scopus, and Web of Science databases using a novel deductive approach to identify relevant scientific papers available in English and focusing on the delivery of telehealth interventions to CF populations as part of or alongside routine CF care. Two relevant reporting checklists were identified in the Equator Network database (Guidelines and Checklist for the Reporting on Digital Health Implementations [iCHECK-DH] and Template for Intervention Description and Replication for Telehealth [TIDiER-telehealth]) to extract data from the papers. Each checklist category was described as being “fully reported” (score=2), “partially reported” (score=1), and “did not report” (score=0) for each paper. An overall score was calculated for adherence to the checklists. Results: In total, 98 studies published between 2006 and May 2025 were included in this review, with the majority appearing during the COVID-19 pandemic (2021-2022). Most studies were conducted in a single country, predominantly the United States, Australia, and the United Kingdom, and were published in medical journals. Telehealth was variably described, with video call–based models in combination with remote monitoring being most common. The median score was 22/40 (range 11-29, 55.0% adherent) for iCHECK and 15/24 (range 6-23, 62.5% adherent) for TIDiER, demonstrating moderate overall reporting quality. For iCHECK, ≥50% of studies fully reported 6/20 categories, partially reported 9/20 categories, and did not report 3/20 categories. For TIDiER, ≥50% of studies fully reported 4/12 categories, partially reported 6/12 categories, and did not report 1/12 categories, indicating persistent gaps in intervention description despite improved partial reporting. Conclusions: Key areas, such as justification for telehealth, target populations, and outcomes, are well documented, offering valuable insights into the rationale for and outcomes associated with telehealth. However, implementation processes remain underreported, partly due to the more recent adoption of frameworks like iCHECK and TIDiER. The clinical implications of the current evidence limit the implementation of telehealth in terms of the ability to assess feasibility and readiness for adoption; understand financial implications and plan sustainably; ensure patient safety, data protection, and equity; interpret outcome data in context; and share, replicate, or scale evidence-based models of care. Strengthening the commitment to standardized telehealth reporting will ultimately support clinical decision-making and improve the effective and equitable integration of telehealth into care.
- 22 May 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e86194
Open AccessReporting of Telehealth Implementation in Cystic Fibrosis: Scoping Review Using a Novel Theory-Based Evaluation Lens
Background: Many inductive reviews exploring telehealth and its application in health care have identified missing or inconsistently reported implementation data, calling for a standardized approach to telehealth research. Objective: Using cystic fibrosis (CF) as a case exemplar, this study evaluated the adherence of telehealth research to standardized reporting frameworks through a theory-based evaluation lens to assess implementation reporting quality and identify knowledge gaps and strengths across the literature. Methods: We conducted an updated systematic review of the PubMed, Scopus, and Web of Science databases using a novel deductive approach to identify relevant scientific papers available in English and focusing on the delivery of telehealth interventions to CF populations as part of or alongside routine CF care. Two relevant reporting checklists were identified in the Equator Network database (Guidelines and Checklist for the Reporting on Digital Health Implementations [iCHECK-DH] and Template for Intervention Description and Replication for Telehealth [TIDiER-telehealth]) to extract data from the papers. Each checklist category was described as being “fully reported” (score=2), “partially reported” (score=1), and “did not report” (score=0) for each paper. An overall score was calculated for adherence to the checklists. Results: In total, 98 studies published between 2006 and May 2025 were included in this review, with the majority appearing during the COVID-19 pandemic (2021-2022). Most studies were conducted in a single country, predominantly the United States, Australia, and the United Kingdom, and were published in medical journals. Telehealth was variably described, with video call–based models in combination with remote monitoring being most common. The median score was 22/40 (range 11-29, 55.0% adherent) for iCHECK and 15/24 (range 6-23, 62.5% adherent) for TIDiER, demonstrating moderate overall reporting quality. For iCHECK, ≥50% of studies fully reported 6/20 categories, partially reported 9/20 categories, and did not report 3/20 categories. For TIDiER, ≥50% of studies fully reported 4/12 categories, partially reported 6/12 categories, and did not report 1/12 categories, indicating persistent gaps in intervention description despite improved partial reporting. Conclusions: Key areas, such as justification for telehealth, target populations, and outcomes, are well documented, offering valuable insights into the rationale for and outcomes associated with telehealth. However, implementation processes remain underreported, partly due to the more recent adoption of frameworks like iCHECK and TIDiER. The clinical implications of the current evidence limit the implementation of telehealth in terms of the ability to assess feasibility and readiness for adoption; understand financial implications and plan sustainably; ensure patient safety, data protection, and equity; interpret outcome data in context; and share, replicate, or scale evidence-based models of care. Strengthening the commitment to standardized telehealth reporting will ultimately support clinical decision-making and improve the effective and equitable integration of telehealth into care.
- Open Access
- 19 March 2026
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (4) , 628-636
Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey
- 19 March 2026
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (4) , 628-636
Open AccessDeterminants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey
- 1 November 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (11) , 1680-1687
Ultra-Low Dose Thoracic Computed Tomography–derived Morphomics in Patients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor
Rationale: In cystic fibrosis (CF), body composition alterations are observed. The prevalence of obesity in CF is increasing, with evidence suggesting a subsequent increase in cardiometabolic risk. We sought to assess body composition using analytic morphomics from ultra-low–dose thoracic computed tomography (CT) scans in patients with CF on the triple CFTR (cystic fibrosis transmembrane conductance regulator) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI). Objectives: Our objective was to use analytical morphomics on routine ultra-low–dose CTs to assess patterns of change in body composition in patients with CF on ETI therapy. Methods: Forty-two patients with CF on ETI who had baseline and follow-up ultra-low–dose thoracic CT imaging were retrospectively analyzed. The CTs were acquired at a radiation dose equivalent to two frontal chest X-rays using our previously published acquisition parameters. The Bhalla score was used as a marker of structural lung disease severity. Analytic morphomics variables, including cross-sectional area and attenuation of pectoralis muscle, visceral fat (epicardial and upper abdominal), and subcutaneous fat, were extracted using the validated image segmentation software CoreSlicer. Paired-samples mean testing (Wilcoxon matched-pairs signed-rank test) and Spearman rank correlation analyses were performed. Results: Total Bhalla scores significantly improved over time in patients on ETI (P < 0.0001). In addition, body composition also changed, with an increase in the cross-sectional area of subcutaneous and epicardial visceral fat (P < 0.0001 and P = 0.0062, respectively). In those with a normal BMI at follow-up, epicardial and subcutaneous fat had also increased significantly in the interval (P = 0.0066 and P = 0.0002, respectively). Conclusions: In CF, ETI produced a significant improvement in structural lung disease over time; however, it also resulted in an increase in visceral and subcutaneous fat. The analytic morphomics methodology presented herein may help identify those patients for aggressive primary prevention strategies and permit the creation of more personalized nutritional plans.
- 1 November 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (11) , 1680-1687
Ultra-Low Dose Thoracic Computed Tomography–derived Morphomics in Patients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor
Rationale: In cystic fibrosis (CF), body composition alterations are observed. The prevalence of obesity in CF is increasing, with evidence suggesting a subsequent increase in cardiometabolic risk. We sought to assess body composition using analytic morphomics from ultra-low–dose thoracic computed tomography (CT) scans in patients with CF on the triple CFTR (cystic fibrosis transmembrane conductance regulator) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI). Objectives: Our objective was to use analytical morphomics on routine ultra-low–dose CTs to assess patterns of change in body composition in patients with CF on ETI therapy. Methods: Forty-two patients with CF on ETI who had baseline and follow-up ultra-low–dose thoracic CT imaging were retrospectively analyzed. The CTs were acquired at a radiation dose equivalent to two frontal chest X-rays using our previously published acquisition parameters. The Bhalla score was used as a marker of structural lung disease severity. Analytic morphomics variables, including cross-sectional area and attenuation of pectoralis muscle, visceral fat (epicardial and upper abdominal), and subcutaneous fat, were extracted using the validated image segmentation software CoreSlicer. Paired-samples mean testing (Wilcoxon matched-pairs signed-rank test) and Spearman rank correlation analyses were performed. Results: Total Bhalla scores significantly improved over time in patients on ETI (P < 0.0001). In addition, body composition also changed, with an increase in the cross-sectional area of subcutaneous and epicardial visceral fat (P < 0.0001 and P = 0.0062, respectively). In those with a normal BMI at follow-up, epicardial and subcutaneous fat had also increased significantly in the interval (P = 0.0066 and P = 0.0002, respectively). Conclusions: In CF, ETI produced a significant improvement in structural lung disease over time; however, it also resulted in an increase in visceral and subcutaneous fat. The analytic morphomics methodology presented herein may help identify those patients for aggressive primary prevention strategies and permit the creation of more personalized nutritional plans.
- Open Access
- 20 October 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Reporting of Telehealth Implementation in Cystic Fibrosis: Scoping Review Using a Novel Theory-Based Evaluation Lens (Preprint)
BACKGROUND Many inductive reviews exploring telehealth and its application in health care have identified missing or inconsistently reported implementation data, calling for a standardized approach to telehealth research. OBJECTIVE Using cystic fibrosis (CF) as a case exemplar, this study evaluated the adherence of telehealth research to standardized reporting frameworks through a theory-based evaluation lens to assess implementation reporting quality and identify knowledge gaps and strengths across the literature. METHODS We conducted an updated systematic review of the PubMed, Scopus, and Web of Science databases using a novel deductive approach to identify relevant scientific papers available in English and focusing on the delivery of telehealth interventions to CF populations as part of or alongside routine CF care. Two relevant reporting checklists were identified in the Equator Network database (Guidelines and Checklist for the Reporting on Digital Health Implementations [iCHECK-DH] and Template for Intervention Description and Replication for Telehealth [TIDiER-telehealth]) to extract data from the papers. Each checklist category was described as being “fully reported” (score=2), “partially reported” (score=1), and “did not report” (score=0) for each paper. An overall score was calculated for adherence to the checklists. RESULTS In total, 98 studies published between 2006 and May 2025 were included in this review, with the majority appearing during the COVID-19 pandemic (2021-2022). Most studies were conducted in a single country, predominantly the United States, Australia, and the United Kingdom, and were published in medical journals. Telehealth was variably described, with video call–based models in combination with remote monitoring being most common. The median score was 22/40 (range 11-29, 55.0% adherent) for iCHECK and 15/24 (range 6-23, 62.5% adherent) for TIDiER, demonstrating moderate overall reporting quality. For iCHECK, ≥50% of studies fully reported 6/20 categories, partially reported 9/20 categories, and did not report 3/20 categories. For TIDiER, ≥50% of studies fully reported 4/12 categories, partially reported 6/12 categories, and did not report 1/12 categories, indicating persistent gaps in intervention description despite improved partial reporting. CONCLUSIONS Key areas, such as justification for telehealth, target populations, and outcomes, are well documented, offering valuable insights into the rationale for and outcomes associated with telehealth. However, implementation processes remain underreported, partly due to the more recent adoption of frameworks like iCHECK and TIDiER. The clinical implications of the current evidence limit the implementation of telehealth in terms of the ability to assess feasibility and readiness for adoption; understand financial implications and plan sustainably; ensure patient safety, data protection, and equity; interpret outcome data in context; and share, replicate, or scale evidence-based models of care. Strengthening the commitment to standardized telehealth reporting will ultimately support clinical decision-making and improve the effective and equitable integration of telehealth into care.
- 20 October 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessReporting of Telehealth Implementation in Cystic Fibrosis: Scoping Review Using a Novel Theory-Based Evaluation Lens (Preprint)
BACKGROUND Many inductive reviews exploring telehealth and its application in health care have identified missing or inconsistently reported implementation data, calling for a standardized approach to telehealth research. OBJECTIVE Using cystic fibrosis (CF) as a case exemplar, this study evaluated the adherence of telehealth research to standardized reporting frameworks through a theory-based evaluation lens to assess implementation reporting quality and identify knowledge gaps and strengths across the literature. METHODS We conducted an updated systematic review of the PubMed, Scopus, and Web of Science databases using a novel deductive approach to identify relevant scientific papers available in English and focusing on the delivery of telehealth interventions to CF populations as part of or alongside routine CF care. Two relevant reporting checklists were identified in the Equator Network database (Guidelines and Checklist for the Reporting on Digital Health Implementations [iCHECK-DH] and Template for Intervention Description and Replication for Telehealth [TIDiER-telehealth]) to extract data from the papers. Each checklist category was described as being “fully reported” (score=2), “partially reported” (score=1), and “did not report” (score=0) for each paper. An overall score was calculated for adherence to the checklists. RESULTS In total, 98 studies published between 2006 and May 2025 were included in this review, with the majority appearing during the COVID-19 pandemic (2021-2022). Most studies were conducted in a single country, predominantly the United States, Australia, and the United Kingdom, and were published in medical journals. Telehealth was variably described, with video call–based models in combination with remote monitoring being most common. The median score was 22/40 (range 11-29, 55.0% adherent) for iCHECK and 15/24 (range 6-23, 62.5% adherent) for TIDiER, demonstrating moderate overall reporting quality. For iCHECK, ≥50% of studies fully reported 6/20 categories, partially reported 9/20 categories, and did not report 3/20 categories. For TIDiER, ≥50% of studies fully reported 4/12 categories, partially reported 6/12 categories, and did not report 1/12 categories, indicating persistent gaps in intervention description despite improved partial reporting. CONCLUSIONS Key areas, such as justification for telehealth, target populations, and outcomes, are well documented, offering valuable insights into the rationale for and outcomes associated with telehealth. However, implementation processes remain underreported, partly due to the more recent adoption of frameworks like iCHECK and TIDiER. The clinical implications of the current evidence limit the implementation of telehealth in terms of the ability to assess feasibility and readiness for adoption; understand financial implications and plan sustainably; ensure patient safety, data protection, and equity; interpret outcome data in context; and share, replicate, or scale evidence-based models of care. Strengthening the commitment to standardized telehealth reporting will ultimately support clinical decision-making and improve the effective and equitable integration of telehealth into care.
- Open Access
- 12 June 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (2) , 2402443
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): Results of a multi-centre randomised controlled trial
Background: This study explores the effectiveness and safety of microbiome-directed-antimicrobial-therapyversususual-antimicrobial-therapy in adult cystic fibrosis pulmonary exacerbations.Methods: A multi-centre two-arm parallel randomised control trial conducted across Europe/North-America enrolled 223 participants (January 2015 - August 2017). All participants were chronically colonised withPseudomonas aeruginosaand were randomised 1:1 into two study-arms. The “usual-therapy group” received 2-weeks of IV ceftazidime 3g thrice-daily (for allergies: aztreonam 2g thrice-daily) and tobramycin 5–10mg·kg−1once-daily. The “microbiome-directed group” received the same usual-therapy plus an additional antibiotic with greatest presumed activity against the 2nd, 3rd and 4th most abundant genera present in the sputum microbiome, selected by a Consensus Expert Treatment Panel. The primary outcome was change in percentage of predicted FEV1(ppFEV1) at 14 days post initiation of antibiotics. Secondary outcomes examined ppFEV1at 7 days, 28 days, and 3 months; time-to-next exacerbation; symptom burden at 7 days; Health Related Quality of Life (HRQoL) at 28 days; and number of exacerbations and IV antibiotic days at 12 months.Results: 149 participants had an eligible exacerbation (usual-therapy n=83, microbiome-directed therapy n=66). There was no difference between the groups for ppFEV1at day 14 (−1.1%, 95%CI −3.9 to 1.7; p=0.46), or ppFEV1measured at other time-points, or for time-to-next exacerbation (microbiome-directedversususual-therapy Hazard Ratio 0.91 [95%CI 0.60 to 1.38; p=0.66]). The microbiome-directed group trended to have more IV days (median 42versus28; p=0.08) and more subsequent exacerbations (median 3versus2; p=0.044) the following year. There were no appreciable differences in symptom burden; however, HRQoL sub-scores were consistently worse in the microbiome-directed group (−4.3 pointsversususual therapy (95%CI −8.3 to −0.3, p=0.033).Conclusion: The addition of a third antibiotic based on sputum microbiome sequencing analysis did not result in improved clinical outcomes.
- 12 June 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (2) , 2402443
Open AccessCystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): Results of a multi-centre randomised controlled trial
Background: This study explores the effectiveness and safety of microbiome-directed-antimicrobial-therapyversususual-antimicrobial-therapy in adult cystic fibrosis pulmonary exacerbations.Methods: A multi-centre two-arm parallel randomised control trial conducted across Europe/North-America enrolled 223 participants (January 2015 - August 2017). All participants were chronically colonised withPseudomonas aeruginosaand were randomised 1:1 into two study-arms. The “usual-therapy group” received 2-weeks of IV ceftazidime 3g thrice-daily (for allergies: aztreonam 2g thrice-daily) and tobramycin 5–10mg·kg−1once-daily. The “microbiome-directed group” received the same usual-therapy plus an additional antibiotic with greatest presumed activity against the 2nd, 3rd and 4th most abundant genera present in the sputum microbiome, selected by a Consensus Expert Treatment Panel. The primary outcome was change in percentage of predicted FEV1(ppFEV1) at 14 days post initiation of antibiotics. Secondary outcomes examined ppFEV1at 7 days, 28 days, and 3 months; time-to-next exacerbation; symptom burden at 7 days; Health Related Quality of Life (HRQoL) at 28 days; and number of exacerbations and IV antibiotic days at 12 months.Results: 149 participants had an eligible exacerbation (usual-therapy n=83, microbiome-directed therapy n=66). There was no difference between the groups for ppFEV1at day 14 (−1.1%, 95%CI −3.9 to 1.7; p=0.46), or ppFEV1measured at other time-points, or for time-to-next exacerbation (microbiome-directedversususual-therapy Hazard Ratio 0.91 [95%CI 0.60 to 1.38; p=0.66]). The microbiome-directed group trended to have more IV days (median 42versus28; p=0.08) and more subsequent exacerbations (median 3versus2; p=0.044) the following year. There were no appreciable differences in symptom burden; however, HRQoL sub-scores were consistently worse in the microbiome-directed group (−4.3 pointsversususual therapy (95%CI −8.3 to −0.3, p=0.033).Conclusion: The addition of a third antibiotic based on sputum microbiome sequencing analysis did not result in improved clinical outcomes.
- Open Access
- 1 April 2025
- Published by AME Publishing Company in mHealth
- Vol. 11, 20
A narrative review of digital health literacy within cystic fibrosis telehealth: are we considering it?
Background and Objective: With the increased adoption of digital health solutions, such as telehealth, there is a need to consider current practices and considerations towards digital health Literacy. The objective of this review is to explore what digital health literacy considerations have been detailed in cystic fibrosis telehealth papers. Methods: The found papers published from a recent systematic review exploring telehealth within cystic fibrosis care were taken and analysed. These papers were obtained from PubMed, Web of Science, and Scopus databases and included any paper written in English up to May 2021. Data pertaining to Health Literacy, Digital Literacy/Competency, Digital Health Literacy, Training, Readiness Assessments, and Sustained Use were extrapolated using Elicit AI Research Assistant 2024. Key Content and Findings: From the 26 papers, the data of interest was sparse and mostly unavailable for this review. This may be due to several reasons; however the implication of this mitigation is discussed with reference to the digital divide, health in-equalities, and safety. Conclusions: This review highlights that a structured approach to assess digital health literacy of care teams and people with cystic fibrosis is critical to the future success of safe telehealth use, and other digital health solutions.
- 1 April 2025
- Published by AME Publishing Company in mHealth
- Vol. 11, 20
Open AccessA narrative review of digital health literacy within cystic fibrosis telehealth: are we considering it?
Background and Objective: With the increased adoption of digital health solutions, such as telehealth, there is a need to consider current practices and considerations towards digital health Literacy. The objective of this review is to explore what digital health literacy considerations have been detailed in cystic fibrosis telehealth papers. Methods: The found papers published from a recent systematic review exploring telehealth within cystic fibrosis care were taken and analysed. These papers were obtained from PubMed, Web of Science, and Scopus databases and included any paper written in English up to May 2021. Data pertaining to Health Literacy, Digital Literacy/Competency, Digital Health Literacy, Training, Readiness Assessments, and Sustained Use were extrapolated using Elicit AI Research Assistant 2024. Key Content and Findings: From the 26 papers, the data of interest was sparse and mostly unavailable for this review. This may be due to several reasons; however the implication of this mitigation is discussed with reference to the digital divide, health in-equalities, and safety. Conclusions: This review highlights that a structured approach to assess digital health literacy of care teams and people with cystic fibrosis is critical to the future success of safe telehealth use, and other digital health solutions.
- Open Access
- 19 November 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Real-world improvement in ultra-low-dose thoracic computed tomography scores, systemic inflammatory markers and patient-reported outcome measures after elexacaftor/tezacaftor/ivacaftor treatment
Background: Clinical trials with elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis were associated with significant improvements in % predicted forced expiratory volume in 1 s (FEV1% pred), sweat chloride, weight and quality of life in the respiratory domain from the cystic fibrosis questionnaire revised (CFQ-R). Limited data exist on its effect on structural lung disease and inflammatory cytokines.Methods: In a real-world setting with 61 people with cystic fibrosis, we prospectively recorded FEV1, sweat chloride, body mass index (BMI) and CFQ-R at baseline, 3 and 6 months after commencement of ETI. In addition, changes in ultra-low-dose (ULD) computed tomography (CT) Bhalla score, peripheral-blood and sputum inflammatory cytokines and patient-reported outcome measures (PROMs), including sino-nasal outcomes test-22 (SNOT-22) and fatigue scale (FACIT-Fatigue).Results: Significant improvements in FEV1% pred (p=0.0001), sweat chloride (p<0.0001) and BMI (p=0.0147) after ETI treatment were noted. ULD-CT scores demonstrated reductions in peri-bronchial thickening, mucus plugging and total Bhalla score (p<0.001), and improvements in emphysema extent (p<0.0027). Improvements in systemic inflammatory status were seen with a reduction in interleukin (IL)-1β (p=0.0049), IL-6 and IL-8 (p<0.0001), and increasing IL-10 (p=0.004). Sputum cytokine analysis was not performed as only four of 61 patients spontaneously expectorated sputum after ETI. PROMs improved significantly for the SNOT-22 (p<0.0001), FACIT-Fatigue score (p=0.0001) and CFQ-R domains, including respiratory (p<0.0001), physical (p=0.007), vitality (p=0.0004), treatment burden (p=0.0028), health (p=0.0007), social (p=0.0073), weight (p=0.0068) and role/school domain (p=0.0018).Conclusion: ETI responders, demonstrate significant improvements in CT imaging, circulating cytokines and PROMs, which may be of further use evaluating cystic fibrosis transmembrane conductance regulator modulation treatment response.
- 19 November 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Open AccessReal-world improvement in ultra-low-dose thoracic computed tomography scores, systemic inflammatory markers and patient-reported outcome measures after elexacaftor/tezacaftor/ivacaftor treatment
Background: Clinical trials with elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis were associated with significant improvements in % predicted forced expiratory volume in 1 s (FEV1% pred), sweat chloride, weight and quality of life in the respiratory domain from the cystic fibrosis questionnaire revised (CFQ-R). Limited data exist on its effect on structural lung disease and inflammatory cytokines.Methods: In a real-world setting with 61 people with cystic fibrosis, we prospectively recorded FEV1, sweat chloride, body mass index (BMI) and CFQ-R at baseline, 3 and 6 months after commencement of ETI. In addition, changes in ultra-low-dose (ULD) computed tomography (CT) Bhalla score, peripheral-blood and sputum inflammatory cytokines and patient-reported outcome measures (PROMs), including sino-nasal outcomes test-22 (SNOT-22) and fatigue scale (FACIT-Fatigue).Results: Significant improvements in FEV1% pred (p=0.0001), sweat chloride (p<0.0001) and BMI (p=0.0147) after ETI treatment were noted. ULD-CT scores demonstrated reductions in peri-bronchial thickening, mucus plugging and total Bhalla score (p<0.001), and improvements in emphysema extent (p<0.0027). Improvements in systemic inflammatory status were seen with a reduction in interleukin (IL)-1β (p=0.0049), IL-6 and IL-8 (p<0.0001), and increasing IL-10 (p=0.004). Sputum cytokine analysis was not performed as only four of 61 patients spontaneously expectorated sputum after ETI. PROMs improved significantly for the SNOT-22 (p<0.0001), FACIT-Fatigue score (p=0.0001) and CFQ-R domains, including respiratory (p<0.0001), physical (p=0.007), vitality (p=0.0004), treatment burden (p=0.0028), health (p=0.0007), social (p=0.0073), weight (p=0.0068) and role/school domain (p=0.0018).Conclusion: ETI responders, demonstrate significant improvements in CT imaging, circulating cytokines and PROMs, which may be of further use evaluating cystic fibrosis transmembrane conductance regulator modulation treatment response.
- Open Access
- 24 May 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 375-387
Standards for the care of people with cystic fibrosis (CF); Planning for a longer life
- 24 May 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 375-387
Open AccessStandards for the care of people with cystic fibrosis (CF); Planning for a longer life